Avalo Therapeutics Inc (AVTX) — Cash Flow-to-Debt Ratio
Avalo Therapeutics Inc (AVTX) has a Cash Flow-to-Debt Ratio of -0.49x as of September 2025, meaning its operating cash flow of $-16.36 Million could theoretically repay 0% of its total liabilities ($33.55 Million) in one year. See Avalo Therapeutics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Avalo Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Avalo Therapeutics Inc across 13 annual periods. For the full cash flow conversion analysis, see Avalo Therapeutics Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Avalo Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Avalo Therapeutics Inc. Check Avalo Therapeutics Inc (AVTX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.77x | $-49.06 Million | $17.70 Million | ▼ -23.7% |
| 2023 | -2.24x | $-30.68 Million | $13.69 Million | ▼ -271.0% |
| 2022 | -0.60x | $-26.75 Million | $44.28 Million | ▲ +51.3% |
| 2021 | -1.24x | $-70.89 Million | $57.13 Million | ▲ +41.3% |
| 2020 | -2.11x | $-40.54 Million | $19.19 Million | ▼ -66.8% |
| 2019 | -1.27x | $-19.13 Million | $15.11 Million | ▼ -1897.1% |
| 2018 | -0.06x | $-3.13 Million | $49.34 Million | ▼ -107.7% |
| 2017 | 0.82x | $12.52 Million | $15.26 Million | ▲ +131.3% |
| 2016 | -2.62x | $-14.57 Million | $5.56 Million | ▼ -121.0% |
| 2015 | -1.19x | $-10.16 Million | $8.57 Million | ▼ -195.2% |
| 2014 | -0.40x | $-15.52 Million | $38.65 Million | ▲ +19.9% |
| 2013 | -0.50x | $-11.49 Million | $22.92 Million | ▲ +91.7% |
| 2012 | -6.02x | $-9.29 Million | $1.54 Million | — |